TARS – Equity Positioning Report
1. Report classification
| Field | Classification | Operational reading |
|---|---|---|
| Risk Exposure | Equity Risk | Exposure is taken through TARS, a mid-cap equity. |
| Horizon | Positioning | The thesis is built on a horizon of weeks to months. |
| Asset | TARS | Tarsus Pharmaceuticals, Healthcare sector, Pharmaceuticals industry. |
| Bias | Constructive | The setup combines Dark Pool accumulations, WPI strength, medium-term relative strength and fundamental growth. |
| Status | Pending confirmation | The stock has broken above the VAT of the trading range and must now convert the $65/$64 area into a valid support. |
| Key Level / Key Condition | Hold of the $65/$64 area | Defence of Rank 1 and Rank 2 supports continuation towards $75, $80 and $85. |
2. Origin of the case
| Element | What we observe | Detail |
|---|---|---|
| Initial trigger | Dark Pools | Accumulations over the past month with Rank 4, Rank 2 and Rank 1, for a total notional value in excess of $400 million. |
| Second evidence | WPI | Stock in the Strong section alongside the reference index, sector and industry. |
| Third evidence | Relative strength | XLV has begun to outperform SPY, and TARS has been outperforming the sector for a considerable time. |
| Reason for deeper analysis | Fundamentals and technical structure | Revenue, margins and EPS expected to grow, with the stock in a long-term uptrend and a trading range showing signs of resolution. |
| Follow-up check | Volume Profile / Options | Monitor the $65/$64, $57.37, $75, $80 and $85 areas. |
TARS enters the watchlist on the convergence of Dark Pool accumulations, a strong WPI ranking, improving relative strength in the Healthcare sector and a technical structure that has begun to break out of the consolidation range built since April 2026. The quality of the setup depends on the price's ability to defend the $65/$64 area and to convert the VAT breakout into a sustainable resumption of trend.
3. Evidence Stack
Rank 4, Rank 2 and Rank 1 over the past month, for over $400 million.
TARS in the Strong section alongside the index, sector and industry.
XLV improving against SPY and TARS outperforming the sector for over two years.
Revenue, margins and EPS expected to grow strongly after years of negative results.
Supports at $65/$64 and $57.37; subsequent resistance levels at $75, $80 and $85.
4. Operational modules of the report
4.1 Dark Pools
FLOW
TARS also enters the watchlist on the presence of significant Dark Pool accumulations over the past month, with the appearance of Rank 4, Rank 2 and Rank 1, for a total notional value in excess of $400 million.
The Rank 1, located around 65,17$, represents the primary volumetric support level for price. In close proximity we also find the Rank 2, situated at 64,61$. The two levels therefore cover the 65/64$ area, which takes on an important role as the first line of defence.
The last volumetric stronghold is represented by the Rank 4, positioned around 57,37$.
4.2 WPI and sector strength
WPI
On the WPI, the stock is positioned in the Strong section, alongside the index, sector and reference industry.
All observed assets are oriented towards the upper portion of the quadrant over the long term, confirming the strength in place both on the stock and across the broader sector.
4.3 Healthcare relative strength
RS
As regards relative strength, the Healthcare sector, represented by XLV, has begun to outperform the SPY index. On the weekly timeframe, the sector reversed its previous downtrend approximately two months ago, bringing the relative strength line back above the 50-period moving average.
TARS has been outperforming the sector for a considerable time. Over recent months, however, the stock has entered a consolidation phase, as reflected in the price action as well. Notwithstanding this, the probability of a renewed breakout in relative strength versus the sector remains high, as it would resume a bullish trend that has been in place for over two years.
4.4 Fundamentals: Revenue, Margins and EPS
FUND

From a fundamental standpoint, the stock displays significant revenue growth. After two negative years, revenues began to grow materially from 2024 onwards, with a year-on-year increase in excess of 900% in 2024 and equal to 146% in 2025.
The company listed in 2021, so it should be noted that the available fundamental history remains limited.
The current P/E and forward estimates are very elevated. This aspect must be contextualised: particularly within the Pharmaceuticals sector, many companies make extensive use of equity-dilutive financing, even in the presence of strong revenue growth.
Margins are also expanding over the past two years. In 2024 they recorded an increase of 438% compared with the prior year, which was negative, while in 2025 they grew by 205% relative to 2024.
EPS estimates point to growth of 580% compared with current EPS, which remain negative. A further increase of 76% is subsequently expected in 2028. Current EPS stand at -0,59, while expected EPS are 2,87 in 2027 and 5,06 in 2028.
4.5 Long-Term Price Action
WEEKLY
From a price action perspective, the stock has been in a bullish trend since 2023. Since the beginning of 2026, however, it has undergone a significant correction, resulting in a decline of approximately 34% from its all-time highs.
Over recent months the stock has traded sideways around a support area and, over the longer term, has begun to show a recovery to the upside.
4.6 Recent Consolidation and Volume Profile
RANGE
The sideways phase that began in April 2026 gave rise to a sweep of the lows and a manipulation event in the first days of June, in correspondence with the Rank 4 level cited previously. The same level was then retested again in the first days of July.
Relative to this ranging area, the stock managed to break above the VAH on 6 July, confirming strength in the subsequent session.
The VAH of the aforementioned distribution corresponds to the 65,20$ area, which is the same zone where Rank 1 is located. This confluence increases the significance of the level as a valid support. Furthermore, with respect to the cumulative volume distribution as well, the same area corresponds to an important Low Volume Node.
4.7 Cumulative Volume Profile and Targets
PROFILE
A possible target for this nascent rally, or price recovery, could be represented by the 80$. This is a significant round number for market participants and also coincides with the upper edge of the last High Volume Node before a return towards the all-time highs.
On the options side, over the next two monthly expiries, relevant levels emerge around 75$ and subsequently around 85$. Open interest on the 80$ is considerably more contained.
This element makes it possible to complement the Volume Profile analysis: the 75$could represent the first obstacle to overcome, while a break of that level could increase the probability of a move towards the 85$. This reading remains valid at the time of writing, as options market positioning can vary from one day to the next.
5. Scenario Map
| Scenario | Condition | Reading | Monitoring Action |
|---|---|---|---|
| Base Case | Holding of the 65/64$ area. | Price defends Rank 1, Rank 2 and VAT of the sideways distribution. | Monitor reaction and acceptance above the former trading range. |
| Upgrade Case | Continuation of the breakout above 65.20$. | The VAT breakout is confirmed as a signal of strength. | Track the approach towards 75$. |
| Extension Case | Break above 75$. | Price may target 80$ and then 85$. | Monitor options and acceptance above the first obstacle. |
| Warning Case | Loss of the 65/64$ area. | The structure loses its first volumetric support. | Watch for a return towards Rank 4 at 57.37$. |
| Invalidation Case | Sustained loss of 57.37$. | The last volumetric bastion of the setup is eliminated. | Place the thesis under review. |
6. Monitoring Plan
| Variable | Frequency | What to Observe | Interpretation | Decision |
|---|---|---|---|---|
| Dark Pool | On new event | New ranks and defence of Rank 1 and Rank 2. | Confirms or weakens the quality of the 65/64$ support. | Update the level map. |
| WPI | Weekly | TARS, XLV, SPY and sector remaining in Strong. | Measures the quality of sector strength. | Upgrade if the trajectory remains towards the upper part of the quadrant. |
| XLV/SPY | Weekly | Relative strength holding above the 50-period moving average. | Confirms the sector driver. | Reduce layer weighting if the sector loses strength. |
| Price 65/64$ | Daily / Weekly | Holding of VAT, Rank 1 and Rank 2. | Confirms the operational support of the setup. | Maintain constructive scenario above the area. |
| Price 57.37$ | Weekly | Potential return to Rank 4. | Last volumetric bastion. | Review in the event of a sustained loss. |
| Options | On open interest change | Levels 75$, 80$ and 85$. | Monthly expirations may alter the upper resistance levels. | Update targets and resistances. |
| Fundamentals | Quarterly | Revenue, margins and expected EPS. | Confirms or reduces the growth thesis. | Update the fundamental picture. |
7. Risk & Invalidation
| Risk Exposure | Risk to Monitor | Typical Invalidation |
|---|---|---|
| Equity Risk | Weakness in the stock, deterioration in expected EPS, or compression of sentiment in mid-cap Healthcare. | Sustained loss of key support levels. |
| Flow Risk | Dark Pool accumulations are not defended by price. | Loss of Rank 1 and Rank 2 in the 65/64$ area. |
| Technical Risk | False breakout above the VAT and return into the trading range. | Failure to achieve acceptance above 65.20$. |
| Options Risk | Open interest levels change rapidly. | Loss of significance of the 75/80/85$ map. |
| Fundamental Risk | Company with a limited track record and elevated multiples, despite revenue growth. | Negative revision of EPS and margin expectations. |
The setup remains constructive only as long as the 65/64$ area is defended. A loss of this zone would reduce the quality of the breakout, while a sustained loss of 57.37$ would place the case under review.
8. Final Decision Box
| Field | Details |
|---|---|
| Risk Exposure | Equity Risk |
| Horizon | Positioning |
| Asset | TARS - Tarsus Pharmaceuticals |
| Final Bias | Constructive, contingent on the defence of the 65/64$ area. |
| Primary Rationale | Dark Pool accumulations in excess of $400 million, WPI in Strong, favourable relative strength, fundamental growth and VAT breakout. |
| What to Monitor | 65.17$, 64.61$, 57.37$, 75$, 80$, 85$, WPI, XLV/SPY and options level updates. |
| Upgrade Condition | Holding of 65/64$ and continuation towards 75$. |
| Downgrade Condition | Return below 65/64$. |
| Invalidation | Sustained loss of Rank 4 in the 57.37$ area. |
The stock displays a convergence of Dark Pool flows, WPI, relative strength, fundamental growth and volume structure. The $65/$64 area represents the first support level to defend. Above this zone, the move can work towards $75, then $80 and subsequently $85, bearing in mind that the options map may shift rapidly over time.
Content (text and/or images) produced with the assistance of artificial intelligence, under the editorial responsibility of the newsroom.